Viromed Medical AG Seeks Approval for PulmoPlas®

Viromed Medical AG has begun the approval process for its new product, PulmoPlas®, with Germany's Federal Institute for Drugs and Medical Devices (BfArM). This step is part of the company's plan to offer a new treatment for severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).

PulmoPlas® utilizes cold plasma technology, positioning it as a novel approach against antimicrobial resistance. Uwe Perbandt, CEO, emphasizes its potential impact on medical challenges, marking the approval process as vital for Viromed and pathogen resistance efforts.

The approval is supported by studies involving Hannover Medical School and the Helmholtz Centre for Infection Research. Additionally, Viromed aims for special approval to expedite PulmoPlas® availability.

Recent studies on VAP treatment using PulmoPlas® in intensive care settings back this initiative. More details are available on Viromed's website.